Figure 2
Patient-derived serum blocks CD20 binding, but not CD45. A comparison of the mean fluorescence intensity of tositumomab and BC8 binding to patient-derived malignant B cells after incubation with rituximab-treated patient-derived serum.
Patient-derived serum blocks CD20 binding, but not CD45. A comparison of the mean fluorescence intensity of tositumomab and BC8 binding to patient-derived malignant B cells after incubation with rituximab-treated patient-derived serum.
